Close Menu

NEW YORK – NantKwest on Monday announced promising Phase I safety data for its immunotherapy targeting PD-L1 expressing tumors. 

The drug candidate, QUILT-3.064, is being evaluated for safety and primary efficacy in six patients with solid tumors expressing PD-L1, a protein that can play a role in eliciting an immune response against cancer cells. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
25

This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts.